Ocugen Secures FDA Alignment for Phase 2/3 Clinical Trial of OCU410ST for Stargardt Disease

Ocugen, a biotech company specializing in gene therapies, has taken a major step toward bringing new hope to Stargardt disease patients. The FDA has greenlit a Phase 2/3 clinical trial for OCU410ST, a potential one-time treatment for this rare genetic eye disorder. This decision accelerates Ocugen’s timeline, with the company aiming for a biologics license application (BLA) submission by 2027. Early trial results are promising, showing a 52% slower lesion growth rate and improved vision in treated patients. With no existing cure, this development offers fresh optimism to the 44,000 U.S. patients affected by the disease.

Dr. Shankar Musunuri, Ocugen’s CEO, expressed excitement about the FDA’s support, calling it a game-changer for those battling vision loss. The upcoming trial will involve 51 participants, with a focus on measuring lesion reduction and vision improvement. Dr. Huma Qamar, Ocugen’s Chief Medical Officer, emphasized how this accelerated timeline could cut years off the approval process, making treatment available sooner. For those living with Stargardt disease, this breakthrough could mean a brighter future, quite literally.